Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Erlotinib in Unresectable Pancreatic Cancer
NCT00837876Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Oct 2008
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib, erlotinib in pancreatic adenocarcinoma (PDAC), sponsored by Vanderbilt-Ingram Cancer Center. Started Oct 2008; status: completed.
02
Drugs
sorafeniberlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00837876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00837876.